GB2065659A - Calciumphosphatidylchlorine- chloride, process for producing the same and pharmaceutical preparations containing the same - Google Patents

Calciumphosphatidylchlorine- chloride, process for producing the same and pharmaceutical preparations containing the same Download PDF

Info

Publication number
GB2065659A
GB2065659A GB8040311A GB8040311A GB2065659A GB 2065659 A GB2065659 A GB 2065659A GB 8040311 A GB8040311 A GB 8040311A GB 8040311 A GB8040311 A GB 8040311A GB 2065659 A GB2065659 A GB 2065659A
Authority
GB
United Kingdom
Prior art keywords
phosphatidylcholine
chloride
calcium
process according
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB8040311A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A Natterman und Cie GmbH
Original Assignee
A Natterman und Cie GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A Natterman und Cie GmbH filed Critical A Natterman und Cie GmbH
Publication of GB2065659A publication Critical patent/GB2065659A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/10Phosphatides, e.g. lecithin
    • C07F9/106Adducts, complexes, salts of phosphatides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)

Abstract

The present invention provides the new compound calcium phosphatidylcholine chloride as well as a process for producing the same wherein phosphatidylcholine and calcium chloride are reacted in a suitable solvent e.g. an aliphatic alcohol or water and pharmaceutical preparations containing the same.

Description

SPECIFICATION Calcium phosphatidylcholine chloride, process for producing the same and pharmaceutical preparations containing the same The present invention is directed to a solid, freeflowing calcium phosphatidylcholine chloride product of high purity which may be readily converted to pharmaceutical preparations. The present invention is further directed to processes for the production of this product and pharmaceutical preparations containing the same.
Lecithin products are phosphorus containing lipids which occur widely in living subject matter as well as in plants. In view of their high physiological importance in various processes of human life, the lecithins have been used for many years in the food industry.
Lecithin products as currently marketed represent a mixture of various components comprising about 35% of oil, phosphatidyl ethanolamine, phosphatidy Icholine, phosphatidylinosite, phosphatidic acid, phosphatidylserine, sterines and other lipids (see for instance Seifen-Ole-Fette-Wachse 1973, vol. 99/6, p.168 to 169). However, only phosphatidylcholine is therapeutically interesting and important from a nutritive physiological point of view (see H. Peters "Phosphatidylcholine", Spring-Verlag 1976).
Phosphatidylcholine is recovered on a large scale as follows: Oil is at first extracted from lecithin containing products by means of acetone. The fraction which is insolubie in acetone thereafter is extracted with ethanol and the extracts are purified by adsorption chromatography. The eluate then is evaporated giving substantially pure phosphatidylcholine.
However, the phosphatidylcholine produced in this manner shows some considerable disadvantages. It is obtained as plastic material which has low stability and is difficult to further process and handle.
Therefore, various efforts have been made to convert this plastic material into a free flowing powder or a liquid of low viscosity by the addition of various auxiliary agents. For instance, proteins have been added (see Japanese Patents Nos. 59/8884 and 62/12401 and USP 2 632 705) or mono- or polysaccharides have been used (see USP 2430 553, 2 057 695 and 3 012 888). All these auxiliary agents however have the disadvantage that they either have to be added in large amounts up to 60% or that they are not acceptable physiologically and therefore cannot be used in pharmaceutical preparations. A further disadvantage of the above process is the use of acetone because acidic phosphatides may cause acetone to form condensation products such as mesityloxide or diacetone alcohol.Phosphatidylcholine obtained according to the above process is contaminated with such condensation products which are not only undesired organoleptically but also have a high toxicity even in small amounts and therefore have to be removed. This purification causes additional costs and work.
It is furthermore known (see German Patent 510 186 and Swiss Patents 127256 and 136 239) that the usual lecithin addition product produced with calcium chloride is recovered as a solid pulervizable product by mixing an alcoholic solution of lecithin with an alcohoiic solution of calcium chloride, treating the resulting solution with acetone and separating the precipitated addition compound from the solution and drying it. This process starts with the usual lecithin product which besides phosphatidy Icholine further contains all other phosphatides such as phosphatidylethanolamine, phosphatidylserine, phosphatidylinosite and other accompanying lipids.
There is obtained by this process therefore an addition compound of this phospholipid mixture with calcium chloride.
According to investigations of H. Hauser and R.M.C. Dafson (see European Journal of Biochemistry 1967, vol. 1, p.63) the affinity of the calcium ions does not exist for all phospholipids but the calcium ions are only bound by the acid phospholipids such as phosphatidic acid, phosphatidylserine, phosphatidylinosite and further accompanying lipids but not to non-acidic lipids such as phosphatidylcholine. The affinity of calcium ions to phosphatidic acid, phosphatidylserine and phosphatidylinosite is used for instance for the removal of such undesired accompanying lipids from lecithin (see USP 3 081 320).
Based on these test results, it must be regarded as impossible to produce useful calcium chloride addition products with pure phosphatidylcholine.
It now has been found that, surprisingly in view of the above, there may be obtained a stable solid calcium phosphatidylcholine chloride of high purity by dissolving phosphatidylcholine in a suitable solvent and adding thereto a solution of calcium chloride in particular proportions and drying the resulting solution in the usual manner. There are obtained particularly favourable results by using an alcohol as solvent both for the phosphatidylcholine and for the calcium chloride, in particular a lower aliphatic alcohol, and by removing the alcohol without the addition of acetone from the resulting solution. A most preferred solvent is ethanol.The amount of calcium chloride added to the phosphatidylcholine is chosen such that the molar ratio of phosphatidylcholine to calcium chloride is between 1:0.5 and 1:2 and preferably 1:0.5, i.e. that 0.5 to 2 moles of calcium chloride are subjected to reaction with each mole of phosphatidylcholine. It is technically preferred to effect drying by means of a drum evaporator or in a spraydrying tower. Afurther advantage of the present process is that water or aqueous alcohol may be used as solvent in place of the aliphatic alcohol by emulsifying the phosphatidylcholine in an aqueous solution of calcium chloride and subjecting the resulting emulsion directly to drying in a spraydrying tower or to lyophiiisation.
The new calcium phosphatidylcholine chloride which is produced by the present process furthermore may be processed more readily than pure phosphatidylcholine. It is a powder or granular product characterized by a high stability and may be readily used for pharmaceutical preparations in view of its high phosphatidylcholine content. The product may be ground, if necessary, to the desired particle size. If desired, the powder or granular product may be compressed into tablets with the addition of usual galenic additives or may be filled into capsules.
There may also be produced stable injection solutions by emulsifying the product in water. A further advantage of the product produced according to the present process is the absence of any acetone reaction products since of course acetone is not used during its preparation and, if such a reaction product was present in the starting material, any reaction product of acetone is separated from the calcium phosphatidylcholine chloride in the present process during the drying step.
The present invention is further illustrated by the following examples without however limiting the same thereto.
Example I 8 kg (10 moles) of phosphatidylcholine and 1.1 kg (10 moles) of CaCI2 are dissolved with stirring in 4500 cc. of ethanol. Ethanol is separated from the resulting solution by means of a drum dryer. The drying conditions are 1200C and 0.05 bar. There is obtained a slighly yellow flaky product which is ground in a hollow mill or a hammer mill to the desired grain size.
Analysis: P 3.49%; N 1.50% Ca 4.42%; Cl 7.55%.
After dissolving the product in chloroform and evaporating the solvent, the product shows unchanged analytical data.
The product is readily soluble in chloroform, may be dissolved with difficulty only in benzene, is insoluble in petroleum ether, ether and acetone and may be readily emulsified in water.
Example 2 8 kg (10 moles) of phosphatidylcholine and 0.55 kg (5 moles) of calcium chloride are dissolved in 3000 cc. of ethanol and the resulting mixture is further processed as described in Example 1.
Analysis: P 3.59%; N 1.70%; Ca 2.30%; CI 4.02%.
Example 3 8 kg (10 moles) of phosphatidylcholine are emulsified in a solution of 1.1 kg (10 moles) of calcium chloride in 20,000 cc. of water and the resulting emulsion is spray dried in a spraydrying tower at 220 C. There is obtained a slightly yellow powder.
Example 4 8 kg (10 mols) of phosphatidylcholine and 0.55 kg.
(5 moles) of calcium chloride are emulsified in 20,000 cc. of water and further processed as described in Example 3.
Example 5 The product obtained according to Example 2 is ground in a hollow mill, sieved (mesh size 0.5 mm), thoroughly mixed with 1% of Aerosil (finely powderous silicic acid with 99.9% ofSiO2 for adsorption purposes prepared by the German company Degussa AG of Frankfurt/Main, Federal Republic of Germany) and 2% of magnesium stearate and filled into capsules.
Example 6 100 g of calcium phosphatidylcholine chloride are emulsified in 900 cc. of water. The resulting solution issterilised and filled into ampoules to obtain a 10% injection solution. If desired, vitamins and other trace products may be added to the injection solution.

Claims (13)

1. Calcium phosphatidylcholine chloride.
2. Calcium phosphatidylcholine chloride having the formula [PC]. [CaC121, wherein PC is a phosphatidylcholine and xis a number from 0.5 to 2.
3. Calcium phosphatidylcholine chloride according to claim 1 which is obtained by subjecting phosphatidylcholine and calcium chloride to reaction in a suitble solvent and evaporating the resulting solution.
4. Calcium phosphatidylcholine chloride according to claim 3 wherein the phosphatidylcholine and calcium chloride are subjected to reaction in a molar proportion of 0.5 to 2 moles of calcium chloride per each mole of phosphatidylcholine.
5. Process according to claim 4 wherein the reaction is carried out in a suitable sovent and the resulting solution or emulsion is subjected to evaporation.
6. Process according to claim 5 wherein the solvent used is an aliphatic alcohol.
7. Process according to claim 6 wherein the solvent used is ethanol.
8. Process according to claim 5 wherein the solvent used is water.
9. Process according to any of claims 5 to 8 wherein phosphatidylcholine and calcium chloride are subjected to reaction in a molar ratio of 1 to 0.5.
10. Process according to any of claims 5 to 9 wherein evaporation is effected with a drum evaporator.
11. Process according to any of claims 5 to 9 wherein evaporation is effected by spraydrying.
12. Process according to any of claims 5 to 9 wherein drying is effected to lyophilisation.
13. Pharmaceutical preparations comprising a calcium phosphatidylcholine chloride according to any of claims 1 to 4 or produced by the process of any of claims 5 to 12.
GB8040311A 1979-12-21 1980-12-17 Calciumphosphatidylchlorine- chloride, process for producing the same and pharmaceutical preparations containing the same Withdrawn GB2065659A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2951681 1979-12-21

Publications (1)

Publication Number Publication Date
GB2065659A true GB2065659A (en) 1981-07-01

Family

ID=6089244

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8040311A Withdrawn GB2065659A (en) 1979-12-21 1980-12-17 Calciumphosphatidylchlorine- chloride, process for producing the same and pharmaceutical preparations containing the same

Country Status (1)

Country Link
GB (1) GB2065659A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6638495B2 (en) 1997-09-29 2003-10-28 Nektar Therapeutics Stabilized preparation for use in metered dose inhalers
US7442388B2 (en) * 2000-05-10 2008-10-28 Weers Jeffry G Phospholipid-based powders for drug delivery
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US8715623B2 (en) 2001-12-19 2014-05-06 Novartis Ag Pulmonary delivery of aminoglycoside
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168223B1 (en) 1997-09-29 2012-05-01 Novartis Pharma Ag Engineered particles and methods of use
US6638495B2 (en) 1997-09-29 2003-10-28 Nektar Therapeutics Stabilized preparation for use in metered dose inhalers
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US20110082076A1 (en) * 2000-05-10 2011-04-07 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8709484B2 (en) 2000-05-10 2014-04-29 Novartis Ag Phospholipid-based powders for drug delivery
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US9439862B2 (en) 2000-05-10 2016-09-13 Novartis Ag Phospholipid-based powders for drug delivery
US7442388B2 (en) * 2000-05-10 2008-10-28 Weers Jeffry G Phospholipid-based powders for drug delivery
US8715623B2 (en) 2001-12-19 2014-05-06 Novartis Ag Pulmonary delivery of aminoglycoside
US9421166B2 (en) 2001-12-19 2016-08-23 Novartis Ag Pulmonary delivery of aminoglycoside

Similar Documents

Publication Publication Date Title
Dittmer et al. The isolation of a new lipid, triphosphoinositide, and monophosphoinositide from ox brain
US4764508A (en) Complexes of flavanolignans with phospholipids, preparation thereof and associated pharmaceutical compositions
JP2528115B2 (en) Pharmaceutical composition containing inositol triphosphite
US4614796A (en) Liposome and method of manufacture therefor
CA1336957C (en) Phospholipid-containing composition, a process for its preparation and its use as an excipient for pharmaceutical substances
DE3537550A1 (en) PHARMACEUTICAL COMPOSITION
EP0078820B1 (en) Inclusion complexes of n-(1-phenylethyl)-3,3-diphenylpropylamine respectively the hydrochloride thereof with cyclodextrin, a process for the preparation of these inclusion complexes as well as pharmaceutical preparations containing these inclusion complexes
EP0145209B1 (en) A kit or device and method for administering gangliosides and derivatives thereof of inhalation and pharmaceutical compositions suitable therefor
GB2065659A (en) Calciumphosphatidylchlorine- chloride, process for producing the same and pharmaceutical preparations containing the same
KR100407088B1 (en) Secondary Phosphoric Acid-Amino Acid Composite Salts, and Additives for Use in Feed for Ruminant Mammals Containing Such Salts
EP1213294B2 (en) Purifying process for phosphatidylserine
US4254115A (en) Phospholipid derivative with an antilipemic and antiarteriosclerotic effect
US4542019A (en) Antacid compositions
EP0054768B1 (en) A process for the separation of acylated phospholipids from phosphatidylcholin products containing them
EP0885896B1 (en) Phospholipid composition
EP1659878B1 (en) Formulation based on phospholipids
JPH0657715B2 (en) Method for producing lysophospholipid containing almost no lysophospholipid other than LPC
EP0406732B1 (en) Highly concentrated and low-viscosity surfactant suspension
EP0521398B1 (en) Phospholipids container composition
JPS6336792A (en) Production of phospholipid by enzyme
GB2051069A (en) Phospholipid Derivatives Useful in Therapy as Antilepaemics and Antiarteriosclerotics and Compositions Containing Them
EP0549794B1 (en) Production of a stock solution of sucralfate suspended in water
WO1983003198A1 (en) A method for dividing blood hemoglobin into heme and globin
EP0841010A1 (en) Stable compositions dispersible in cold water
JPS6341920B2 (en)

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)